BRPI0511907A - novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina - Google Patents

novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina

Info

Publication number
BRPI0511907A
BRPI0511907A BRPI0511907-3A BRPI0511907A BRPI0511907A BR PI0511907 A BRPI0511907 A BR PI0511907A BR PI0511907 A BRPI0511907 A BR PI0511907A BR PI0511907 A BRPI0511907 A BR PI0511907A
Authority
BR
Brazil
Prior art keywords
phenylpiperidine
modulators
dopamine neurotransmission
new disubstituted
piperizine
Prior art date
Application number
BRPI0511907-3A
Other languages
English (en)
Inventor
Clas Sonesson
Lars Swanson
Nicholas Waters
Original Assignee
Carlsson A Research Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0401464A external-priority patent/SE0401464D0/xx
Priority claimed from SE0403142A external-priority patent/SE0403142D0/sv
Application filed by Carlsson A Research Ab filed Critical Carlsson A Research Ab
Publication of BRPI0511907A publication Critical patent/BRPI0511907A/pt
Publication of BRPI0511907A8 publication Critical patent/BRPI0511907A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4

Abstract

NOVOS DERIVADOS DE FENILPIPERIDINAS/PIPERAZINAS DISSUBSTITUìDOS COMO MODULADORES DA NEUROTRANMISSãO DE DOPAMINA A presente invenção refere-se a compostos que possuem efeitos terapêuticos contra distúrbios do sistema nervoso central e, em particular, a novos compostos de 4-(fenil) -1-lquilpiperidinas e piperazinas -orto, meta-dissubstituidos, de fórmula (I), onde R~ 1~, R~ 2~, R~ 3~ e Y são como definido no presente relatório.
BRPI0511907A 2004-06-08 2005-06-08 novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina BRPI0511907A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57795304P 2004-06-08 2004-06-08
SE0401464A SE0401464D0 (sv) 2004-06-08 2004-06-08 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
US63753004P 2004-12-20 2004-12-20
SE0403142A SE0403142D0 (sv) 2004-12-20 2004-12-20 New disubstituted phenylpiperidines/-piperazines as modulators of dopamine neurotransmission
PCT/EP2005/006147 WO2005121087A1 (en) 2004-06-08 2005-06-08 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission

Publications (2)

Publication Number Publication Date
BRPI0511907A true BRPI0511907A (pt) 2008-01-15
BRPI0511907A8 BRPI0511907A8 (pt) 2018-05-02

Family

ID=42727310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511907A BRPI0511907A8 (pt) 2004-06-08 2005-06-08 novos derivados de fenilpiperidinas/piperazinas dissubstituídos como moduladores da neurotransmissão de dopamina

Country Status (12)

Country Link
EP (3) EP1773772B1 (pt)
JP (2) JP4937124B2 (pt)
AT (2) ATE449070T1 (pt)
AU (2) AU2005251906B2 (pt)
BR (1) BRPI0511907A8 (pt)
CA (2) CA2569840C (pt)
DK (1) DK1773772T3 (pt)
ES (1) ES2346452T3 (pt)
NZ (2) NZ552409A (pt)
PL (1) PL1773772T3 (pt)
PT (1) PT1773772E (pt)
WO (2) WO2005121088A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
DE602005017784D1 (de) 2004-06-08 2009-12-31 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008239841B2 (en) 2007-04-12 2013-07-18 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
KR20100033419A (ko) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
JP2011524917A (ja) * 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103037843A (zh) 2010-06-23 2013-04-10 麦它波莱克斯股份有限公司 5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
JP6189299B2 (ja) 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
CN104470585A (zh) 2012-04-04 2015-03-25 爱华克斯国际有限公司 用于联合疗法的药物组合物
BR112015019208A2 (pt) * 2013-02-14 2017-07-18 Galderma Res & Dev processo de síntese
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EP3150591A1 (en) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Process and intermediates for the preparation of benzo[b]thiophene compounds
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
JP7278210B2 (ja) * 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP2022509965A (ja) 2018-12-03 2022-01-25 ハー・ルンドベック・アクチエゼルスカベット ４－（（１Ｒ，３Ｓ）－６－クロロ－３－フェニル－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－１，２，２－トリメチルピペラジン及び４－（（１Ｒ，３Ｓ）－６－クロロ－３－（フェニル－ｄ５）－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－２，２－ジメチル－１－（メチル－ｄ３）ピペラジンのプロドラッグ

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) * 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (pt) 1964-04-14
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
EP0094159B1 (en) * 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives, their production and use
US4504660A (en) * 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
AU6976191A (en) 1989-12-22 1991-07-24 Smithkline Beecham Corporation Anti-viral compositions
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
WO1997003986A1 (fr) * 1995-07-19 1997-02-06 Yoshitomi Pharmaceutical Industries, Ltd. Composes fusionnes de triazole
JPH09151186A (ja) * 1995-09-29 1997-06-10 Yoshitomi Pharmaceut Ind Ltd 縮合トリアゾール化合物
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
SI1196129T1 (sl) 1999-06-25 2006-04-30 Az Univ Amsterdam Farmacevtski in kozmeticni sestavki, ki obsegajo derivate urokaninske kisline kot odstranjevalce radikalov ali antioksidante
WO2001000146A1 (en) 1999-06-28 2001-01-04 The Procter & Gamble Company Cosmetic compositions
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
EP1313477A4 (en) * 2000-07-15 2004-03-03 Smithkline Beecham Corp COMPILATIONS AND METHODS
US7186715B2 (en) * 2001-01-08 2007-03-06 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
WO2005121087A1 (en) 2005-12-22
AU2005251909A1 (en) 2005-12-22
AU2005251906A1 (en) 2005-12-22
EP2204363A1 (en) 2010-07-07
JP4937124B2 (ja) 2012-05-23
ES2346452T3 (es) 2010-10-15
WO2005121088A1 (en) 2005-12-22
ATE469885T1 (de) 2010-06-15
EP1773772B1 (en) 2010-06-02
JP2008501749A (ja) 2008-01-24
PT1773772E (pt) 2010-10-04
EP1768958A1 (en) 2007-04-04
CA2569843A1 (en) 2005-12-22
BRPI0511907A8 (pt) 2018-05-02
NZ552411A (en) 2010-04-30
EP1768958B1 (en) 2009-11-18
CA2569840C (en) 2012-04-17
ATE449070T1 (de) 2009-12-15
CA2569840A1 (en) 2005-12-22
AU2005251906B2 (en) 2011-03-31
PL1773772T3 (pl) 2010-11-30
JP2008501747A (ja) 2008-01-24
EP1773772A1 (en) 2007-04-18
NZ552409A (en) 2010-04-30
DK1773772T3 (da) 2010-09-13

Similar Documents

Publication Publication Date Title
BRPI0511907A (pt) novos derivados de fenilpiperidinas/piperizinas dissubstituìdos como moduladores da neurotransmissão de dopamina
ATE494277T1 (de) 3, 5-disubstituierte phenyl-piperidine als modulatoren der dopamin- neurotransmission
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
GB0510141D0 (en) Novel compounds B3
CO5700748A2 (es) Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
BRPI0818581A2 (pt) Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
NO20070124L (no) Nye disubstituerte fenylpiperidiner/piperaziner som modulatorer av dopamin neurotransmisjon
ATE534625T1 (de) Substituierte n-phenyl-bipyrrolidinharnstoffe und deren therapeutische verwendung
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
ATE532514T1 (de) Piperidin- und piperazinderivate
DK1976525T3 (da) Piperidin- og piperazinderivater
ATE468118T1 (de) Bis-1,2,3,4-tetrahydroisochinolinderivate und ihre verwendung als pharmazeutika
ATE534638T1 (de) Piperazin-derivate
SE0401464D0 (sv) New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
EA200602080A1 (ru) Пиперазиновые производные алкилоксиндолов
MXPA06013945A (es) Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK

Free format text: TRANSFERIDO DE: NEUROSEARCH SWEDEN AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]